Antonella Chadha Santuccione, MD, Co-founder and CEO of the Women’s Brain Project and Chief Medical Officer at Altoida Inc., shares her thoughts on the potential of digital biomarkers in the dementia space. The currently available scales used in clinical trials have several limitations. Most importantly, they lack the precision needed to detect subtle changes in the early stages of disease. Additionally, the impact of intra- and inter-rater variability hinders their robustness. Dr Chadha Santuccione believes digital biomarker panels will be able to overcome these issues, enabling rapid and frequent assessment of patients over time. These measures can detect subtle alterations and patterns that may not otherwise be detected, and can be used on a large scale in a remote setting. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
